A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting
Diabetes, Obesity and Metabolism Mar 09, 2018
Seaquist ER, et al. - Researchers resolved to figure out the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycemic events (HEs) in adults with type 1 diabetes (T1D). Data displayed that NG was easy to use, as revealed via most caregivers. It was noted that maximum adverse events were local and of low-to-moderate severity. Hence, a single, 3-mg dose of NG was discovered to be effective in treating moderate and severe HEs in adults with T1D. Furthermore, NG appeared to be well tolerated and easy to use.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
